Eli Lilly Buys Versanis to Boost Its Obesity Drug Portfolio
Eli Lilly agreed to buy biopharma firm Versanis for up to $1.93 billion, boosting Lilly's reach into the obesity drug market.
Eli Lilly agreed to buy biopharma firm Versanis for up to $1.93 billion, boosting Lilly's reach into the obesity drug market.
:max_bytes(150000):strip_icc()/amazon-logo-56a8fc825f9b58b7d0f7019e.jpg){kind=logo}
/what-to-do-when-you-blow-your-budget-1-5baec65fc9e77c00263c49c0.jpg){kind=small}
:max_bytes(150000):strip_icc():format(jpeg)/mortgage-rates-5094943-39167b5a777f45869b0769f7f9ec18bb.gif?#){kind=small}
